Smith & Nephew: US bank upbeat after meetings with management

Citi reiterated its "buy" rating on Smith & Nephew following management meetings, citing a constructive tone despite maintained full-year guidance due to global uncertainties and tough comparisons. The bank noted encouraging momentum in US orthopaedics and strong growth in Sports and Wound care, underscoring the company's strategic focus on accelerating non-orthopaedics growth organically and through M&A, with no plans to divest its core orthopaedics segment. Shares remained flat at 1,342p following the update.

Analysis

Following meetings with Smith & Nephew's CEO and CFO, Citi has reiterated its 'buy' rating, signaling confidence in the company's operational trajectory despite management's decision to maintain full-year guidance. This cautious stance on guidance is attributed to prevailing global uncertainties and challenging fourth-quarter comparables. Operationally, the company is demonstrating encouraging momentum within its US orthopaedics division, where hip replacements are outperforming, although the knee segment lags slightly with a stated goal to match market growth by year-end. The Sports and Wound care divisions are also identified as strong performers, particularly in markets outside of China. Strategically, Smith & Nephew is focusing on accelerating growth in its non-orthopaedics businesses through both organic initiatives and smaller acquisitions, while firmly dismissing any plans to divest its core orthopaedics segment. However, investors should note that challenges are anticipated for its ear, nose, and throat treatments and skin substitutes businesses in 2026. The market's response was neutral, with the stock trading flat at 1,342p, suggesting the positive analyst commentary was balanced by the unchanged outlook.

Key Decisions for Investors

• Investors may consider the reiterated 'buy' rating and strong performance in the US hips, Sports, and Wound care segments as support for a bullish thesis, further reinforced by management's commitment to the core orthopaedics business.
• It is prudent to monitor the company's ability to achieve its year-end goal of matching market growth in its knee segment, as the decision to hold guidance steady indicates significant external headwinds or execution risk.
• Pay close attention to the execution of the non-orthopaedics growth strategy via M&A, and factor in the specifically identified headwinds for the ENT and skin substitute businesses projected for 2026.